View posters, expert perspectives, and downloadable slides from our symposium at the 2017 Breast Cancer Annual Meeting in San Antonio Experts discuss current treatment approaches, biology, and novel treatment strategies for triple-negative breast cancer (TNBC), including antibody-drug conjugates, targeted therapies, PARP inhibitors, and immunotherapy.
0.5 AMA PRA Category 1 Credit™
Dec 21, 2017
Dec 21, 2018
Harold J. Burstein, MD, PhDDana-Farber Cancer Institute
Boston, Massachusetts, United States
Giuseppe Curigliano, MD, PhDEuropean Institute of Oncology
University of Milan
Joyce O’Shaughnessy, MDBaylor University Medical Center
Dallas, Texas, United States
Jorge S. Reis-Filho, MD, PhD, FRCPathMemorial Sloan Kettering Cancer Center
New York, New York, United States
Andrew Tutt, MD, PhDInstitute of Cancer Research
London, United Kingdom
Current treatment approaches: How I manage my patients
Harold J. Burstein, MD, PhD
Getting to grips with the biology of TNBC
Jorge Reis-Filho, MD, PhD
Aim at the heart: The opportunities provided by antibody-drug conjugates and targeted therapies in TNBC
Joyce O’Shaughnessy, MD
PARP inhibition in TNBC: Who, how, and when?
Andrew Tutt, MD, PhD
Immunotherapy for TNBC: Hope or hype?
Giuseppe Curigliano, MD, PhD
Posters relating to this activity:
- Adjuvant Capecitabine Improves Long-Term Survival in Patients With Triple-Negative Breast Cancer: Results from the FinXX and CREATE-X Trials
- nab-Paclitaxel + Carboplatin or Gemcitabine vs Gemcitabine + Carboplatin as First-Line Treatment for Patients With Triple-Negative Metastatic Breast Cancer: Results From the Randomized Phase II Portion of the tnAcity Trial
- Ipatasertib Plus Paclitaxel vs Placebo Plus Paclitaxel as First-Line Therapy for Metastatic Triple-Negative Breast Cancer (LOTUS): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Trial
- Efficacy and Safety of Anti–Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- Pembrolizumab Plus Standard Neoadjuvant Therapy for High-Risk Breast Cancer: Results From the I-SPY 2 Trial
- Phase II Study of Pembrolizumab Monotherapy for Previously Treated Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Cohort A
- Adaptive Phase II Randomized Noncomparative Trial of Nivolumab After Induction Treatment in Triple-Negative Breast Cancer First Results of the TONIC Trial
- OlympiAD: Olaparib for Metastatic Breast Cancer in Patients With a Germline BRCA Mutation
- Talazoparib in Advanced Breast Cancer Patients With Germline BRCA1/2 Mutations
- Veliparib in Patients with BRCA1 or BRCA2 Mutations and Locally Advanced or Metastatic Breast Cancer
This educational activity is specifically designed for medical oncologists and other healthcare professionals who treat and manage patients with breast cancer.
After successful completion of this educational activity, participants should be able to:
- Assess current and emerging clinical trial information concerning the use of investigational therapeutic approaches to care for patients with TNBC
- Select the most appropriate treatment based upon patient and disease characteristics
This educational activity is supported by grants from AstraZeneca; Merck and Co, Inc.; and TESARO, Inc.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring activity is provided by prIME Oncology.
Method of Participation
Links to the posttest are available on the video player pages.
In order to receive credit, participants must successfully complete the online posttest with 75% or higher.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Burstein has nothing to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Curigliano discloses that he has received consulting fees from Pfizer and Samsung. He also discloses that he has received honoraria from Pfizer and Roche, and that he is a member on an advisory committee or review panel for Lilly and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr O’Shaughnessy discloses that she has received consulting fees from AstraZeneca, Celgene, Lilly, Novartis, and Pfizer. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Reis-Filho has nothing to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Tutt discloses that he has received consulting fees from AstraZeneca, Merck Serono, and Vertex. He has also disclosed independent contractor work for AstraZeneca, and has served on an advisory committee or review panel for AstraZeneca and Merck Serono. He has received royalties from the ICR Rewards to Inventor’s Scheme. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Robert Coleman, MD, FRCP, FRCPE (medical director content reviewer/planner) –performed contracted research for or received research support from Amgen and Bayer
- Amy Furedy, RN, OCN (scientific content reviewer/planner) – no relevant financial relationships
- Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.